Insider Selling: Adaptive Biotechnologies (NASDAQ:ADPT) Insider Sells 11,000 Shares of Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) insider Susan Bobulsky sold 11,000 shares of the stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $18.00, for a total transaction of $198,000.00. Following the sale, the insider owned 416,775 shares of the company’s stock, valued at approximately $7,501,950. This represents a 2.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Susan Bobulsky also recently made the following trade(s):

• On Wednesday, March 11th, Susan Bobulsky sold 41,338 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $13.17, for a total transaction of $544,421.46.

Adaptive Biotechnologies Stock Down 1.2%

Shares of Adaptive Biotechnologies stock traded down $0.20 during trading on Monday, reaching $16.70. 1,749,340 shares of the stock were exchanged, compared to its average volume of 1,691,541. The stock’s fifty day moving average is $14.22 and its 200 day moving average is $15.65. The firm has a market cap of $2.67 billion, a price-to-earnings ratio of -50.61 and a beta of 2.16. Adaptive Biotechnologies Corporation has a 1 year low of $9.90 and a 1 year high of $20.76.

Adaptive Biotechnologies (NASDAQ:ADPT) last posted its earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.03. The company had revenue of $70.87 million during the quarter, compared to analyst estimates of $61.03 million. Adaptive Biotechnologies had a negative net margin of 16.82% and a negative return on equity of 40.06%. Adaptive Biotechnologies’s revenue for the quarter was up 35.1% on a year-over-year basis. During the same period in the prior year, the business posted ($0.20) earnings per share. Equities analysts forecast that Adaptive Biotechnologies Corporation will post -0.48 earnings per share for the current year.

Hedge Funds Weigh In On Adaptive Biotechnologies

A number of institutional investors have recently bought and sold shares of ADPT. Westfield Capital Management Co. LP bought a new position in Adaptive Biotechnologies in the fourth quarter worth about $65,942,000. Price T Rowe Associates Inc. MD raised its stake in Adaptive Biotechnologies by 303.4% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,387,361 shares of the company’s stock worth $71,252,000 after buying an additional 3,299,635 shares in the last quarter. Ameriprise Financial Inc. raised its stake in Adaptive Biotechnologies by 84.3% in the third quarter. Ameriprise Financial Inc. now owns 5,971,706 shares of the company’s stock worth $89,337,000 after buying an additional 2,731,648 shares in the last quarter. Invesco Ltd. raised its stake in Adaptive Biotechnologies by 248.8% in the fourth quarter. Invesco Ltd. now owns 3,107,653 shares of the company’s stock worth $50,468,000 after buying an additional 2,216,595 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership raised its stake in Adaptive Biotechnologies by 544.0% in the third quarter. Arrowstreet Capital Limited Partnership now owns 2,441,402 shares of the company’s stock worth $36,523,000 after buying an additional 2,062,282 shares in the last quarter. 99.17% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of analysts have recently weighed in on ADPT shares. Morgan Stanley dropped their target price on shares of Adaptive Biotechnologies from $21.00 to $18.00 and set an “equal weight” rating for the company in a report on Tuesday, May 12th. JPMorgan Chase & Co. decreased their price target on shares of Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating for the company in a research note on Wednesday, May 6th. Guggenheim reissued a “buy” rating and issued a $21.00 price target on shares of Adaptive Biotechnologies in a research note on Wednesday, May 6th. BTIG Research reissued a “buy” rating and issued a $22.00 price target on shares of Adaptive Biotechnologies in a research note on Wednesday, May 6th. Finally, Wall Street Zen downgraded shares of Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a research note on Saturday, March 7th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $19.57.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.